Perspektywy leczenia farmakologicznego tętniczego nadciśnienia płucnego

Chronic cor pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser. 1961;213:35.

Humbert M. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. European Respiratory Journal. 2004;24(3):353-359. doi:10.1183/09031936.04.00028404

Peacock AJ, Murphy NF, McMurray JJ v., Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal. 2007;30(1):104-109. doi:10.1183/09031936.00092306

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237

Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and Diagnosis of Pulmonary Hypertension. J Am Coll Cardiol. 2013;62(25):D42-D50. doi:10.1016/j.jacc.2013.10.032

Tamimi O, Mohammed MHA. Pulmonary Vascular Resistance Measurement Remains Keystone in Congenital Heart Disease Management. Front Cardiovasc Med. 2021;8. doi:10.3389/fcvm.2021.607104

Badlam JB, Badesch DB, Austin ED, et al. United States Pulmonary Hypertension Scientific Registry. Chest. 2021;159(1):311-327. doi:10.1016/j.chest.2020.07.088

Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014;141(2):172-191. doi:10.1016/j.pharmthera.2013.10.002

Parikh V, Bhardwaj A, Nair A. Pharmacotherapy for pulmonary arterial hypertension. J Thorac Dis. 2019;11(S14):S1767-S1781. doi:10.21037/jtd.2019.09.14

Seo B, Oemar BS, Siebenmann R, von Segesser L, Lüscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89(3):1203-1208. doi:10.1161/01.CIR.89.3.1203

Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling 1. The FASEB Journal. 1995;9(12):1196-1204. doi:10.1096/fasebj.9.12.7672512

Ohlstein EH, Arleth A, Bryan H, Elliott JD, Cheng Po Sung. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. European Journal of Pharmacology: Molecular Pharmacology. 1992;225(4):347-350. doi:10.1016/0922-4106(92)90109-9

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. The Lancet. 2001;358(9288):1119-1123. doi:10.1016/S0140-6736(01)06250-X

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(9):809-818. doi:10.1056/NEJMoa1213917

Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 2008;117(23):3010-3019. doi:10.1161/CIRCULATIONAHA.107.742510

Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ET B receptors. J Appl Physiol. 1996;81(4):1510-1515. doi:10.1152/jappl.1996.81.4.1510

Park M, Sandner P, Krieg T. cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway. Basic Res Cardiol. 2018;113(4):24. doi:10.1007/s00395-018-0679-9

Lux A, Pokreisz P, Swinnen M, et al. Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. Journal of Pharmacology and Experimental Therapeutics. 2016;356(2):284-292. doi:10.1124/jpet.115.227850

Runo JR, Loyd JE. Primary pulmonary hypertension. The Lancet. 2003;361(9368):1533-1544. doi:10.1016/S0140-6736(03)13167-4

Mitani Y, Zaidi SHE, Dufourcq P, Thompson K, Rabinovitch M. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP‐mediated suppression of ERK phosphorylation and AML1B nuclear partitioning. The FASEB Journal. 2000;14(5):805-814. doi:10.1096/fasebj.14.5.805

Mandegar M, Fung YCB, Huang W, Remillard C v., Rubin LJ, Yuan JXJ. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res. 2004;68(2):75-103. doi:10.1016/j.mvr.2004.06.001

Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med. 2012;52(9):1970-1986. doi:10.1016/j.freeradbiomed.2012.02.041

Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2013;369(4):330-340. doi:10.1056/NEJMoa1209655

Christman BW, McPherson CD, Newman JH, et al. An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension. New England Journal of Medicine. 1992;327(2):70-75. doi:10.1056/NEJM199207093270202

Galiè N, Manes A, Branzi A. Prostanoids for Pulmonary Arterial Hypertension. American Journal of Respiratory Medicine. 2003;2(2):123-137. doi:10.1007/BF03256644

Rosenkranz S, Channick R, Chin KM, et al. The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail. 2022;24(1):205-214. doi:10.1002/ejhf.2369

Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. Journal of Investigative Medicine. 2021;69(7):1270-1280. doi:10.1136/jim-2021-002027

Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2021;384(13):1204-1215. doi:10.1056/NEJMoa2024277

Derynck R, Zhang Y, Feng XH. Transcriptional Activators of TGF-β Responses: Smads. Cell. 1998;95(6):737-740. doi:10.1016/S0092-8674(00)81696-7

Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. European Respiratory Journal. Published online August 30, 2022:2201347. doi:10.1183/13993003.01347-2022

Torres F, Farber H, Ristic A, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal. 2019;54(4):1901030. doi:10.1183/13993003.01030-2019

Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D13-21. doi:10.1016/j.jacc.2013.10.035

Morrell NW, Yang X, Upton PD, et al. Altered Growth Responses of Pulmonary Artery Smooth Muscle Cells From Patients With Primary Pulmonary Hypertension to Transforming Growth Factor-β 1 and Bone Morphogenetic Proteins. Circulation. 2001;104(7):790-795. doi:10.1161/hc3201.094152

Yang X, Long L, Southwood M, et al. Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension. Circ Res. 2005;96(10):1053-1063. doi:10.1161/01.RES.0000166926.54293.68

David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109(5):1953-1961. doi:10.1182/blood-2006-07-034124

Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells. Journal of Biological Chemistry. 2009;284(23):15794-15804. doi:10.1074/jbc.M109.002881

Jerkic M, Kabir MG, Davies A, et al. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res. 2011;92(3):375-384. doi:10.1093/cvr/cvr232

Hong KH, Lee YJ, Lee E, et al. Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension. Circulation. 2008;118(7):722-730. doi:10.1161/CIRCULATIONAHA.107.736801

Trembath RC, Thomson JR, Machado RD, et al. Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine. 2001;345(5):325-334. doi:10.1056/NEJM200108023450503

Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. European Respiratory Journal. 2012;39(2):329-343. doi:10.1183/09031936.00187310

Sobolewski A, Rudarakanchana N, Upton PD, et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet. 2008;17(20):3180-3190. doi:10.1093/hmg/ddn214

Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation. 2013;123(8):3600-3613. doi:10.1172/JCI65592

Spiekerkoetter E, Sung YK, Sudheendra D, et al. Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. European Respiratory Journal. 2017;50(3):1602449. doi:10.1183/13993003.02449-2016

Dunmore BJ, Drake KM, Upton PD, Toshner MR, Aldred MA, Morrell NW. The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Hum Mol Genet. 2013;22(18):3667-3679. doi:10.1093/hmg/ddt216

Michorowska S. Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner. Pharmaceuticals. 2021;14(8):785. doi:10.3390/ph14080785

Machado RD, Aldred MA, James V, et al. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006;27(2):121-132. doi:10.1002/humu.20285

Thomson JR. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000;37(10):741-745. doi:10.1136/jmg.37.10.741

Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA. Correction of Nonsense BMPR2 and SMAD9 Mutations by Ataluren in Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol. 2013;49(3):403-409. doi:10.1165/rcmb.2013-0100OC

Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015;21(7):777-785. doi:10.1038/nm.3877

Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y shan. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17(1):36. doi:10.1186/s12943-018-0801-5

Shimoda LA, Laurie SS. Vascular remodeling in pulmonary hypertension. J Mol Med. 2013;91(3):297-309. doi:10.1007/s00109-013-0998-0

Csósza G, Karlócai K, Losonczy G, Müller V, Lázár Z. Growth factors in pulmonary arterial hypertension: Focus on preserving right ventricular function. Physiol Int. 2020;107(2):177-194. doi:10.1556/2060.2020.00021

Schermuly RT. Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation. 2005;115(10):2811-2821. doi:10.1172/JCI24838

Abe K, Toba M, Alzoubi A, et al. Tyrosine Kinase Inhibitors Are Potent Acute Pulmonary Vasodilators in Rats. Am J Respir Cell Mol Biol. 2011;45(4):804-808. doi:10.1165/rcmb.2010-0371OC

Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. Am J Respir Crit Care Med. 2010;182(9):1171-1177. doi:10.1164/rccm.201001-0123OC

Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 2013;127(10):1128-1138. doi:10.1161/CIRCULATIONAHA.112.000765

ClinicalTrials.gov Identifier: NCT01179737.

Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008;33(2):278-291. doi:10.1152/physiolgenomics.00169.2007

Morrell NW, Adnot S, Archer SL, et al. Cellular and Molecular Basis of Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2009;54(1):S20-S31. doi:10.1016/j.jacc.2009.04.018

Hartmann S, Ridley AJ, Lutz S. The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. Front Pharmacol. 2015;6. doi:10.3389/fphar.2015.00276

Zhang Y, Wu S. Effects of fasudil on pulmonary hypertension in clinical practice. Pulm Pharmacol Ther. 2017;46:54-63. doi:10.1016/j.pupt.2017.08.002

Yamamura A, Nayeem MJ, Sato M. The Rho kinase 2 (ROCK2)-specific inhibitor KD025 ameliorates the development of pulmonary arterial hypertension. Biochem Biophys Res Commun. 2021;534:795-801. doi:10.1016/J.BBRC.2020.10.106

Chen D, Yuan T, Chen Y, et al. DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension. Eur J Pharmacol. 2022;919:174779. doi:10.1016/J.EJPHAR.2022.174779

Condon DF, Agarwal S, Chakraborty A, et al. Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension. Chest. 2022;161(4):1060-1072. doi:10.1016/j.chest.2021.10.010

Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6-30. doi:10.1111/bph.15016

Kawut SM, Archer-Chicko CL, DeMichele A, et al. Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2017;195(3):360-368. doi:10.1164/rccm.201605-1024OC

ClinicalTrials.Gov Identifier: NCT03229499.

Hajra A, Safiriyu I, Balasubramanian P, et al. Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Curr Probl Cardiol. Published online April 2022:101236. doi:10.1016/j.cpcardiol.2022.101236

ClinicalTrials.gov Identifier: NCT03528902.

Gao YM, Feng ST, Wen Y, Tang TT, Wang B, Liu BC. Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215. doi:10.1016/j.ebiom.2022.104215

Vallon V. Renoprotective Effects of SGLT2 Inhibitors. Heart Fail Clin. 2022;18(4):539-549. doi:10.1016/j.hfc.2022.03.005

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

Wheeler DC, Stefansson B v, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation. 2020;35(10):1700-1711. doi:10.1093/ndt/gfaa234

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486

Chowdhury B, Luu V, Luu A, et al. THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES MORTALITY IN EXPERIMENTAL PULMONARY HYPERTENSION. Canadian Journal of Cardiology. 2019;35(10):S32-S33. doi:10.1016/j.cjca.2019.07.415

Chowdhury B, Luu AZ, Luu VZ, et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun. 2020;524(1):50-56. doi:10.1016/j.bbrc.2020.01.015

Zhao YD, Courtman DW, Ng DS, et al. Microvascular Regeneration in Established Pulmonary Hypertension by Angiogenic Gene Transfer. Am J Respir Cell Mol Biol. 2006;35(2):182-189. doi:10.1165/rcmb.2005-0115OC

Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of Monocrotaline-Induced Pulmonary Arterial Hypertension Using Bone Marrow–Derived Endothelial-Like Progenitor Cells. Circ Res. 2005;96(4):442-450. doi:10.1161/01.RES.0000157672.70560.7b

ClinicalTrials.gov Identifier: NCT03001414.

van der Feen DE, Kurakula K, Tremblay E, et al. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019;200(7):910-920. doi:10.1164/rccm.201812-2275OC

Nickel NP, Spiekerkoetter E, Gu M, et al. Elafin Reverses Pulmonary Hypertension via Caveolin-1–Dependent Bone Morphogenetic Protein Signaling. Am J Respir Crit Care Med. 2015;191(11):1273-1286. doi:10.1164/rccm.201412-2291OC

Cheng Y, Gong Y, Qian S, et al. Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats. J Med Chem. 2018;61(4):1474-1482. doi:10.1021/acs.jmedchem.7b01153

Carpenter D, Keller L, Palacios M, et al. ONCE DAILY ORAL DOSING OF RODATRISTAT ETHYL (RVT-1201) ACHIEVES REDUCTIONS IN SEROTONIN BIOSYNTHESIS COMPARABLE TO THOSE ASSOCIATED WITH REVERSAL OF VASCULAR REMODELING IN PAH ANIMAL MODELS. Chest. 2019;156(4):A1175-A1176. doi:10.1016/j.chest.2019.08.1068